drugset / Trial / NCT04940273

Drug Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage

NCT04940273

Unknown 30 enrolled Capital Medical University
NaSingle-groupOpen-labelTreatment

Summary

Although spontaneous hyperventilation patients with aneurysmal subarachnoid hemorrhage closely associated with poor outcomes, the standard therapy remains unavailable. Remifentanil has the pharmacological characterization of respiratory inhibition, mainly prolonging the expiratory time and decreasing the respiratory rate while preserving the respiratory drive. The investigators hypothesis that spontaneous hyperventilation could be corrected by titrating the dose of remifentanil and cerebral blood flow will augment during this process.

Timeline

Start
2021-06-01
Primary completion
2021-12-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 0.08 ug/kg